Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 667 results for kidney or kidneys or renal

  1. Chronic kidney disease: managing anaemia (NG8)

    This guidance has been updated and replaced by NICE guideline NG203.

  2. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  3. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.

  4. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)

    Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.

  5. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

  6. Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTE27)

    Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers....

  7. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.

  8. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

  9. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (CG73)

    This guidance has been updated and replaced by NICE guideline CG182.

  10. What is the optimal timing of administration of carbohydrate drinks as part of a preoperative fasting strategy?

    crystalloid use has become more common after reports of increased risks of acute kidney injury, coagulopathy and mortality with colloid....

  11. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

  12. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

  13. Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.

  14. Acute kidney injury: prevention, detection and management (CG169)

    This guidance has been updated and replaced by NICE guideline NG148.

  15. Chronic kidney disease (stage 5): peritoneal dialysis (CG125)

    This guidance has been updated and replaced by NICE guideline NG107.